GRANULES vs MARKSANS: Stock Comparison

GRANULES INDIA vs MARKSANS PHARMAUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

GRANULES INDIA is the larger company by market capitalisation. GRANULES INDIA shows faster revenue growth, while MARKSANS PHARMA shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

GRANULES leads 2; MARKSANS leads 11 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

GRANULESMARKSANS

Valuation lens

What price are you paying?

Market CapContext only
₹21,073 Cr
₹14,877 Cr
P/E RatioMARKSANS has the lower reading
31.03x
29.56x
P/B RatioGRANULES has the lower reading
4.08x
5.05x
EPSMARKSANS has the higher reading
₹2.9
₹3.47
Book ValueContext only
₹205.21
₹67.36
Dividend YieldMARKSANS has the higher reading
0.21%
0.28%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
GRANULES is the larger company
₹21,073 Cr vs ₹14,877 Cr
P/E Ratio
MARKSANS has a lower P/E
29.56x vs 31.03x
P/B Ratio
GRANULES has a lower P/B
4.08x vs 5.05x
EPS
MARKSANS has higher earnings per share
₹3.47 vs ₹2.9
Dividend Yield
MARKSANS has a higher dividend yield
0.28% vs 0.21%
Revenue Growth (TTM YoY)
GRANULES has faster revenue growth
22.8% vs 20.8%
EPS Growth (TTM YoY)
MARKSANS has faster EPS growth
63.5% vs 31.3%
Qtr Sales Growth
MARKSANS has stronger quarterly sales growth
161.78% vs -45.7%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricGRANULESMARKSANS
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricGRANULESMARKSANS
Live Price₹848.3₹326.75
Day Change-0.65%-1.64%
Volume11.73 L16.54 L
52-Week High₹910₹345.5
52-Week Low₹507.3₹155
Distance from 52W High-6.78%-5.43%

Valuation

MetricGRANULESMARKSANS
Market Cap₹21,073 Cr₹14,877 Cr
P/E Ratio31.03x29.56x
P/B Ratio4.08x5.05x
EPS₹2.9₹3.47
Book Value₹205.21₹67.36
Dividend Yield0.21%0.28%

Growth

MetricGRANULESMARKSANS
Revenue Growth (TTM YoY)22.8%20.8%
EPS Growth (TTM YoY)31.3%63.5%
Qtr Sales Growth-45.7%161.78%
Qtr Profit Growth-60.13%130.9%

Profitability & Leverage

MetricGRANULESMARKSANS
ROE11.7%13.76%
ROCE12.47%17.9%
Net Margin11.15%14.16%
Operating Margin16.76%19.81%
Debt to Equity0.26x0.01x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricGRANULESMARKSANS
Promoter Holding37.67%43.87%
FII Holding17.5% 2.19 pp17.47% 0.71 pp
DII Holding16.11% 0.9 pp6.19% 0.38 pp
Public Holding28.38% 1.28 pp32.47% 0.32 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: GRANULES INDIA and MARKSANS PHARMA.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.